UK Report Calls for Mandatory Breast Implant Registry, Ban on High-Risk Cosmetic Procedures
Introduction
The House of Commons Women and Equalities Committee has released a comprehensive report examining the safety and regulation of cosmetic procedures in the UK. The report sheds light on significant patient safety failures, especially in the context of breast implants and cosmetic treatments—both surgical and non-surgical. It identifies gaps in data collection, informed consent, and clinical oversight, and calls for urgent government action to protect patients, particularly women, from preventable harm.
Patient Safety Failures and Key Terms Explained
A central issue highlighted is the lack of robust regulation in the fast-growing cosmetic industry, leaving patients exposed to risks. The Breast and Cosmetic Implant Registry (BCIR) is a national database set up in October 2016 after the Poly Implant Prothèse (PIP) breast implant scandal. Its purpose is to track breast implant procedures and outcomes, helping monitor patient safety. However, participation in the BCIR is currently voluntary, meaning only about 80% of procedures are recorded. This voluntary reporting limits the quality of information available to patients and clinicians.
The report emphasises that without mandatory reporting and regular publication of outcome data, surgeons cannot fully inform patients of the risks before surgery. According to Carl Heneghan, Director of the Centre for Evidence-Based Medicine at the University of Oxford, “This situation effectively prevents patients from giving fully informed consent.” He adds, “There are lots of uncertainties because of our failures to collect and report an evidence base, as we do for many other implants; the national joint registry for hips and knees does a much better job monitoring the failings of metal hips. However, we are in a world now where complications are increasing, and we have a duty to collate and report evidence appropriately.”
Recommendations: Clear Steps and Responsible Agencies
The Committee recommends that the Department of Health and Social Care require all clinics and hospitals performing breast implant procedures to submit data to the BCIR, including details of implant and explant operations and any adverse outcomes. The Medicines and Healthcare products Regulatory Agency (MHRA) should conduct annual audits of submitted data and publish outcome statistics by implant type. To protect patients, a mandatory cooling-off period of at least two weeks between initial consultation and surgery should be enforced. Enforcement measures could include regular compliance checks and penalties for non-reporting clinics.
Case Study: PIP Scandal and Surveillance Failures
The report revisits the PIP breast implant scandal, where roughly 47,000 UK women received implants made with low-grade silicone by the French company Poly Implant Prothèse. These implants were banned in 2010 due to higher rupture rates—two to six times the standard, according to a 2012 Department of Health expert group. A 2013 study found a rupture rate of 35% among explanted PIP implants.
Despite assurances from the MHRA that PIP implants carry no greater long-term health risk, expert Michael Coleman, Professor of Toxicology at Aston University, disputes this, stating, “Silicones and siloxane compounds released from ruptured implants persist in patients’ bodies for years and may stimulate immune system activity linked to both Breast Implant Illness (BII) and Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).” He further notes, “Even after removal, silicones from the implants can be detected in women’s blood for years. The idea that this is not a problem is simply wrong.”
The Committee recommends that the MHRA regularly test approved breast implant products for material substitution and enforce stricter post-market surveillance. The Department of Health and Social Care should oversee these tests, with the MHRA publishing annual results and issuing recalls when necessary.
Emerging Health Concerns: BIA-ALCL and Breast Implant Illness
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare cancer of the immune system—distinct from breast cancer—that can develop around breast implants. First defined by the World Health Organization in 2016, BIA-ALCL has been mostly linked to textured implants. As of December 2024, the MHRA had received 114 confirmed UK cases, with an estimated risk of 1 in 12,187 implants. Experts caution that cases are likely underreported, as private clinics often do not examine removed tissue under a microscope. Professor Prabath Nanayakkara of Amsterdam University Medical Center notes, “You have to look for it to find it. There is definitely under-reporting.”
In March 2023, the US Food and Drug Administration (FDA) highlighted the emergence of Breast Implant-Associated Squamous Cell Carcinoma, a rare but aggressive tumour linked to breast implants. The FDA called for greater awareness and reporting, while the UK continues to rely on informed consent and clinician disclosure rather than bans, as seen in France and Australia.
Breast Implant Illness (BII) refers to a cluster of symptoms—fatigue, joint pain, cognitive difficulties, hair loss, depression, and gastrointestinal problems—reported by some breast implant patients. Though BII is not formally recognised by the WHO and lacks a validated test, the MHRA has received about 1,000 reports since 2008, representing 0.5% of operations. Research cited in the report found that implant removal provided significant symptom relief for two-thirds of affected patients, though the exact mechanisms remain unclear.
The Committee recommends that the Department of Health and Social Care commission new clinical and long-term studies on breast implant health impacts, especially for patients with autoimmune conditions. The MHRA and NHS should alert primary care providers to possible links between implants and autoimmune symptoms, so patients are not dismissed without investigation.
Non-Surgical Procedures: “Liquid BBLs” and Regulatory Challenges
Non-surgical cosmetic procedures, such as injectable botulinum toxins (anti-wrinkle treatments), dermal fillers, laser therapy, and chemical peels, are widely performed. The liquid Brazilian butt lift (liquid BBL) is a procedure where dermal fillers are injected to increase buttock volume, without surgery. The report describes the current regulatory environment as a “wild west,” with procedures happening in unsafe settings (e.g., Airbnbs, hotel rooms, garden sheds). In June 2025, 28 people were hospitalised after anti-wrinkle injections caused botulism, and in September 2024, Alice Webb became the first UK fatality after a liquid BBL. Save Face, a government-approved register of aesthetic practitioners, has assisted over 700 women with complications from such procedures.
The Committee recommends that the Department of Health and Social Care restrict liquid BBLs and liquid breast augmentations to qualified medical professionals, with enforcement by the MHRA and Care Quality Commission. This would effectively ban most such procedures, as credentialed practitioners rarely perform them. A broader licensing system for lower-risk treatments should be introduced during the current Parliament, with Save Face providing oversight and public reporting.
Training and Certification: Addressing Gaps
Currently, any doctor on the UK medical register can legally perform invasive cosmetic operations in the private sector, regardless of their surgical training. Nigel Mercer, consultant plastic surgeon and former president of professional surgical associations, told the Committee, “A GP or any doctor with minimal training in surgery is allowed to perform invasive cosmetic surgery. We would not allow a GP to perform neuro or cardiac surgery, but the law has double standards for cosmetic treatments.”
The Intercollegiate Cosmetic Surgery Certification Scheme was established in January 2017 to address some of these gaps, but participation remains voluntary. The Committee recommends that the General Medical Council require all practitioners performing invasive cosmetic surgery to hold relevant board certification for each procedure. Enforcement should include annual reviews, mandatory certification checks, and penalties for non-compliance.
Conclusion
The Women and Equalities Committee’s report makes clear, actionable recommendations to improve patient safety and regulatory oversight in the UK’s cosmetic industry. It calls for mandatory recording of breast implant procedures, regular audits and publication of outcome data, targeted bans on high-risk non- surgical treatments, and stricter requirements for surgical training and certification. These steps—led by the Department of Health and Social Care, MHRA, NHS, General Medical Council, and Save Face—are essential to ensure that patients receive safe, informed, and regulated care. Comprehensive oversight and transparent reporting will help restore confidence and protect public health.